Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-15 May 2025

The Committee re-elected Johan Schefferlie from the Netherlands as its Chair for a further 3-year mandate. The Committee adopted by consensus a positive opinion for a marketing authorisation from Intervet International B.V. for Innovax-ND-IBD-ILT, for the active immunisation of one-day-old chicks or 18-19 day-old embryonated chicken eggs to reduce mortality and clinical signs caused by Newcastle disease (ND) virus and to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ILT) virus, Marek’s disease (MD) virus and infectious bursal disease (IBD) virus. The Committee adopted by consensus a positive opinion for a marketing authorisation from Intervet International B.V. for Fluralaner Intervet (fluralaner) for the treatment of flea and tick infestations in dogs for one month. It can also be used as part of a treatment strategy for the control of flea allergy dermatitis. In addition, it reduces the risk of infection with Babesia canis canis and Dipylidium caninum via transmission from ticks and fleas. The Committee adopted by consensus a positive opinion for a marketing authorisation from Intervet International B.V. for Nobilis Multriva IBm+ND+Gm+REOm+EDS, for the active immunisation of chickens for reduction of respiratory signs and egg drop caused by infectious bronchitis virus (IBV) strains Massachusetts (GI-1 genotype) and 4/91-793B (GI-13 genotype); reduction of mortality and clinical signs caused by Newcastle disease virus (NDV);...